0.27
+0.0219(+8.93%)
Currency In USD
Address
75/76 Wimpole Street
London, W1G 9RT
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 8004 0270
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
January 06, 2014
| Name | Title | Pay | Year Born |
| Abizer Gaslightwala | Chief Executive Officer, President & Director | 1,796 | 1974 |
| Torsten Hombeck | Consultant | 290,700 | 1970 |
| Kameel D. Farag | Interim Chief Financial Officer | 540,343 | 1978 |
| Satyajit Mitra | Executive Director & Head of Oncology | 0 | 1975 |
| Mark F. Kubik | Head of Business Development - Oncology | 0 | 1965 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.